Commentary|Podcasts|April 10, 2026

Why Branding is Pharma’s Most Undervalued Asset

Ken Banta and Andy Milligan explore how life sciences leaders can rebuild relevance, consistency, and trust in today's complex and cost-focused era of healthcare.

In this episode of Pharmaceutical Executive’s podcast series Leading Edge With Ken Banta, The Vanguard Network founder and CEO is joined by branding strategist Andy Milligan, founding partner of The Caffeine Partnership, where the duo examine why life sciences companies urgently need to rethink how they build, protect, and communicate their brands.

From the erosion of trust in pharma to the disconnect between scientific innovation and patient experience, the discussion surfaces a core challenge: companies must evolve beyond product-centric messaging to patient-centric storytelling and emotional connection. The conversation also probes the unique tensions in healthcare — where cost, value, and trust collide — and outlines how leaders can retool brand engagement across stakeholders, including physicians, patients, payers, and investors.

Highlights of the discussion with Michael Christel, MJH Life Sciences group managing editor, include:

  • Relevance + consistency = brand durability. Milligan underscores that strong brands evolve with customers while maintaining a clear, consistent identity — something many biopharma companies struggle to balance.
  • Trust is pharma’s defining — and fragile — currency. From pricing scrutiny to commercialization skepticism, the industry faces a persistent trust gap that branding must actively address.
  • The science-to-experience disconnect. While early-stage innovation earns high trust, that credibility often erodes at commercialization, creating a messaging challenge around value, cost, and access.
  • Storytelling as a strategic lever, especially in rare disease. Patient-centric narratives and simpler, more emotive messaging can bridge gaps across stakeholders and strengthen engagement across the care journey.

Milligan advises CEOs and senior management teams on strategies for developing and exploiting brands and growing their business. He is a regular speaker at conferences internationally and has made frequent appearances in media, including on BBC, Sky, and CNN. Milligan has also published six best-selling books.


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Pharmaceutical Executive daily
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Pharmaceutical executive daily
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.